Business Wire

Sosei Provides an Update on Its Immuno-Oncology Clinical Program with AstraZeneca

Del

Sosei Group Corporation (“Sosei” or the “Company”) (TOKYO: 4565), the world leader in GPCR medicine design and development, announces that its immuno-oncology collaboration with AstraZeneca is progressing well. The first patient has been dosed in an expansion cohort in the Phase 1b segment of the Phase 1 study in advanced solid tumours. Furthermore, a new clinical study including AZD4635 to investigate novel combination therapies in EGFRm non-small cell lung cancer is expected to begin in the first quarter 2018.

AZD4635 is a potent and selective, orally available, small molecule adenosine A2A receptor (A2AR) antagonist discovered by Sosei subsidiary Heptares Therapeutics and licensed to AstraZeneca in 2015.

AZD4635 is currently in a Phase 1 clinical trial for patients with advanced solid malignancies, the primary objective of which is to determine maximum tolerated dose (MTD) of AZD4635 alone and in combination with AstraZeneca’s anti-PD-L1 antibody durvalumab. Phase 1b expansion cohorts in advanced solid tumours, are now open and the first patient has been dosed. The trial, sponsored by AstraZeneca, is expected to complete in the second half of 2019. For information on this study please refer to clinicaltrials.gov, trial # NCT02740985.

AstraZeneca, with its global biologics research and development affiliate, MedImmune, is also planning a new clinical study to assess safety, tolerability and anti-tumour activity of novel combination therapies in subjects with advanced epidermal growth factor receptor (EGFRm) mutated non-small cell lung cancer (NSCLC). This Phase 1b/2* study will evaluate the combination of MEDI9447 (an anti-CD73 antibody developed by MedImmune) with AZD4635 or TAGRISSO® (osimertinib), an EGFR tyrosine kinase inhibitor for NSCLC developed by AstraZeneca. For information on this study please refer to clinicaltrials.gov, trial #NCT03381274.

“We are pleased with the progress made with AZD4635 in the Phase 1 clinical study under our partnered immuno-oncology program with AstraZeneca. We are also delighted that AstraZeneca and MedImmune are evaluating AZD4635 in a new clinical study in combination with the anti-CD73 antibody, MEDI9447 in EGFRm non-small cell lung cancer,” commented Dr. Tim Tasker, Sosei’s Chief Medical Officer. “Blocking adenosine-mediated immune suppression is an attractive new mechanism for treating a range of cancers and development of this novel candidate could result in a potential new treatment as a monotherapy or in combination to improve the efficacy of checkpoint inhibitors and other drug classes.”

* Entry into initial new Phase 1b study does not trigger a milestone payment

Notes to Editors

About AZD4635

AZD4635 is a potent and selective, orally available, small molecule adenosine A2A receptor (A2AR) antagonist discovered by Sosei subsidiary Heptares Therapeutics and licensed to AstraZeneca in 2015. AZD4635 blocks A2A receptor signalling and prevents an evolved survival mechanism of tumours from being effective at the level of the immune cell. By stimulating A2A receptors, adenosine, a natural anti-inflammatory molecule, is released preventing T-cells within the immune system from being activated and reduces their ability to destroy cancer cells. A2A receptor antagonism can therefore promote the anti-cancer response of T-cells within the tumour microenvironment, offering a novel mechanism of action as a mono- or combination therapy.

About Sosei

Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company’s leading clinical programs include a proprietary Phase 2 candidate for dementia with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and immuno-oncology approaches to treat cancer (with AstraZeneca). Sosei’s additional partners and collaborators include Novartis, Teva, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.

Sosei is listed on the Mothers Index of the Tokyo Stock Exchange (TOKYO: 4565). For more information, please visit http://www.sosei.com/en/.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact information

Sosei Group Corporation
Chris Cargill, +44 (0)7912 892 199
Head of Investor Relations and Corporate Communications
ccargill@sosei.com
or
Sosei Group Corporation
Harumi Banse, +81 3 5210 3399
Corporate Communications (Japan)
hbanse@sosei.com
or
Citigate Dewe Rogerson (for International media)
Mark Swallow / David Dible, +44 (0)20 7638 9571
sosei@citigatedewerogerson.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Moody’s Names Mona Breed as Chief Information Officer25.9.2018 20:30Pressemelding

Moody’s Corporation (NYSE:MCO) announced today that Mona Breed will join the company as Chief Information Officer (CIO), effective October 15, 2018. As CIO, Ms. Breed will lead Moody’s global technology infrastructure and programs. She will report to Raymond McDaniel, President and Chief Executive Officer of Moody’s. “With nearly 30 years of experience embedding innovation and technology programs at leading financial and professional services firms, Mona’s insight and expertise will be invaluable as we enhance our technology capabilities and leverage our investments,” said Raymond McDaniel President and Chief Executive Officer of Moody’s. Prior to joining Moody’s, Ms. Breed led IT infrastructure for Oppenheimer Funds, where she drove innovation and transformation, including the firm’s cloud computing, unified communication and collaboration, data center operations and workplace technologies. She has also held senior technology roles at PricewaterhouseCoopers and Apollo. Ms. Breed succe

IWBI Announces First WELL Portfolio Participants25.9.2018 18:00Pressemelding

The International WELL Building Institute™ (IWBI™) announced today the first participants in WELL Portfolio™, a new streamlined pathway for WELL Certification™ for multiple new or existing buildings and tenant spaces in a single portfolio. Being released as part of the WELL v2™ pilot, the latest iteration of the WELL Building Standard™ (WELL™), it is part of a suite of enhancements to WELL that addresses growing demand across the building industry for a program that helps owners, developers and tenants streamline and scale health and wellness upgrades to their real estate assets. The announcement quickly follows the launch of WELL v2, the second iteration of IWBI’s pioneering WELL Building Standard. The addition of an early phase review process enabling projects to seek the WELL D&O™ designation, introduced in WELL v2, allows portfolio projects to move through the certification process in a more streamlined and systematic fashion across their asset base, with a specific focus on polici

Mobile Industry Accelerating Delivery of Sustainable Development Goals, According to Latest GSMA Report25.9.2018 17:00Pressemelding

The global mobile industry is demonstrating significant and measurable impact in contributing to the UN’s Sustainable Development Goals (SDGs) and is strengthening its commitment to improving lives around the world, according to a new GSMA study. The 2018 edition of the GSMA’s annual ‘Mobile Industry Impact’ report, published at the UN General Assembly this week, found that the industry has continued to increase its contribution against all 17 Goals since mobile become the first sector in the world to commit to delivery of the SDGs in 2016. This growing impact reflects mobile’s unprecedented global scale, which provides a platform to connect unconnected communities, reduce poverty, improve access to healthcare and education, and drive sustainable economic growth. “More than two-thirds of the people on the planet are now connected to a mobile network and, for many, mobile is the primary – sometimes only – channel for accessing the internet and life-enhancing services,” commented Mats Gr

PMI: Taking Bold Action for Global Change: a Conversation on Tobacco Today and Transformation for Tomorrow25.9.2018 15:43Pressemelding

During the 2018 Concordia Annual Summit, taking place in September 24 & 25 in New York, André Calantzopoulos, CEO of Philip Morris International, delivered a speech highlighting the need to have a dialogue between the industry, leaders, policy-makers, scientists, medical, and public health professionals in order to provide the 1.1 billion people who smoke with better alternatives to cigarettes. The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact. The remarks by André Calantzopoulos follow: “I'm the Chief Executive Officer of a tobacco company. I’m here today because, as global leaders come together in New York for the United Nations General Assembly, this is the time and place to discuss today's problems and their potential solutions. “Smoking tobacco is a behavioral risk factor

ExaGrid Achieves a Net Promoter Score of +7325.9.2018 15:22Pressemelding

ExaGrid ®, a leading provider of hyper-converged secondary storage for backup, today announced that the company has achieved a Net Promoter Score (NPS) of +73 in response to a recently conducted NPS survey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005883/en/ The NPS customer loyalty metric measures how likely existing customers are to recommend a vendor’s product or service to a colleague. The resulting NPS score can be as low as -100 or as high as +100. Most of ExaGrid’s competitors have an NPS of between +10 and +20 versus ExaGrid at +73. We attribute the satisfaction of our customers to our unique product architecture, the fact that the product “just works,” and also to a unique support model: Each customer is assigned to a senior level 2 support tech. Customers consistently deal with the same support tech who virtually becomes an extension of the customer’s IT team; the tech knows the customer, their environm

Abu Dhabi International Hunting and Equestrian Exhibition 2018 Opens its Doors Today25.9.2018 15:17Pressemelding

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in Al Dhafra Region, Chairman of the Emirates Falconers’ Club, the 16th Edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) was inaugurated at Abu Dhabi National Exhibition Center (ADNEC), which will run until 29th September, and celebrates this year the centennial of the late Sheikh Zayed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005875/en/ Scenes from ADIHEX - (Photo: AETOSWire) The event is organized by the Emirates Falconers’ Club and is supported by the Environment Agency - Abu Dhabi (EAD), International Fund for Houbara Conservation (IFHC), the Department of Culture and Tourism (DCT) and The Cultural Programs and Heritage Festivals Committee in addition to many local, regional and international media partners. The main sponsor is His Highness Sheikh Mansoor bin Zayed Al Nahyan Global A